Continuous renal replacement therapy in acute renal failure: Membranes for CRRT

Artificial Organs

Volumn 22, Issue 1, 1998, Pages 2-7

  Jones, Colin H ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RENAL FAILURE; RENAL REPLACEMENT THERAPIES;

CUPROPHANE; INTERLEUKIN 1; POLY(METHYL METHACRYLATE); POLYACRYLONITRILE; POLYAMIDE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE KIDNEY FAILURE; BIOCOMPATIBILITY; BLOOD CLOTTING; COMPLEMENT ACTIVATION; CONFERENCE PAPER; DIALYSIS MEMBRANE; FILTER; HEMODIALYSIS; HUMAN; HYPOTENSION; KIDNEY INJURY; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0031940451     PISSN: 0160564X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1594.1998.06071.x     Document Type: Conference Paper

References (49)

1. Kierdorf H, Sieberth HG. Continuous treatment modalities in acute renal failure. Nephrol Dial Transplant 1995;10:2001-8.
2. Bellomo R, Tipping P, Boyce N. Continuous veno-venous hemofiltration with dialysis removes cytokines from the circulation of septic patients. Crit Care Med 1993;21:522-6.
3. Hoffmann JN, Hartl WH, Deppisch R, Faist E, Jochum M, Inthorn D. Effect of haemofiltration on haemodynamics and systemic concentrations of anphylotoxins and cytokines in human sepsis. Intens Care Med 1996;22:1360-7.
4. Epstein FH. Mechanisms of disease: Pathogenetic mechanisms of septic shock. N Engl J Med 1993;328:1471-7.
5. Lee WM. Medical progress: Acute liver failure. N Engl J Med 1993;329:1862-72.
6. Hakim RM. Clinical implications of hemodialysis membrane biocompatibility (editorial). Kidney Int 1993;44:484-94.
7. Cheung AK, Parker CJ, Wilcox LA, Janatova J. Activation of complement by hemodialysis membranes: Polyacrylonitrile binds more C3a than Cuprophan. Kidney Int 1990;37:1055-9.
8. Verresen L, Fink E, Lemke H-D, Vanrenterghemy. Bradykinin is a mediator of anaphylactoid reactions during haemodialysis with AN69 membranes. Kidney Int 1994;45:1497-1503.
9. Luger A, Kovarik J, Stummvoll HK, Urbanska A, Luger TA. Blood-membrane interaction in hemodialysis leads to increased cytokine production. Kidney Int 1987;32:84-8.
10. Himmelfarb J, Lazarus M, Hakim R. Reactive oxygen species production by monocytes and polymorphonuclear leukocytes during dialysis. Am J Kidney Dis 1991;3:271-6.
11. Schulman G, Fogo A, Gung A, Badr K, Hakim R. Complement activation retards resolution of acute ischemic renal failure in the rat. Kidney Int 1991;40:1069-74.
12. Kranzlin B, Reuss A, Gretz N, Kirschfink M, Ryan CJ, Mujais SK. Recovery from ischemic acute renal failure: Independence from dialysis membrane type. Nephron 1996;73:644-51.
13. Schiffl H, Lang SM, Konig A, Strasser T, Haider MC, Held E. Biocompatible membranes in acute renal failure: Prospective case-controlled study. Lancet 1994;344:570-2.
14. Pertosa G, Tarantino EA, Gesualdo L, Montinaro V, Schena FP. C5b-9 generation and cytokine production in hemodialyzed patients. Kidney Int 1993;41(Suppl):S221-5.
15. de Backer WA, Verpooten GA, Borgonjon DJ, Vermeire PA, Lins RR, de Broe ME. Hypoxemia during hemodialysis: Effect of different membranes and dialysate compositions. Kidney Int 1983;23:738-43.
16. Rosenkranz AR, Templ E, Traindl O, Heinzl H, Zlabinger GJ. Reactive oxygen product formation by human neutrophils as an early marker for biocompatibility of dialysis membranes. Clin Exp Immunol 1994;98:300-5.
17. Walker PD, Shah SV. Evidence suggesting a role for hydroxyl radical in gentamicin-induced acute renal failure in rats. J Clin Invest 1988;81:334-41.
18. Davenport A, Davison AM, Will EJ. Membrane biocompatibility: Effects on cardiovascular stability in patients on hemofiltration. Kidney Int 1993;41(Suppl):S230-4.
19. Akizawa T, Kinugasa E, Wakasa M, Kohjiro S, Koiwa F, Koshikawa S. Effect of dialysis membranes and ACE inhibitor on bradykinin levels during haemodialysis. Clin Nephrol 1994;41:241-4.
20. Mannstadt M, Touam M, Fink E, Urena P, Hruby M, Zingraff J, Grassmann A, Lemke H, Drücke T. No generation of bradykinin with a new PAN membrane (SPAN) in dialysis patients treated with ACE inhibitors (abstract). Nephrol Dial Transplant 1995;10:1036.
21. Guastoni C, Tetta C, Teatini U, Sgro I, Hoenich NA, Civati G. Platelet activating factor (PAF) in hemodialysis with polyacrylonitrile membranes (abstract). Nephrol Dial Transplant 1995;10:1034.
22. Adler AJ, Berlyne GM. Beta thromboglobulin and platelet factor-4 levels during haemodialysis with polyacrylonitrile. ASAIO J 1981;4:100-2.
23. Sreehran N, Crow MJ, Salter MCP, Donaldson DR, Rajah SM, Davison AM. Membrane effect on platelet function during hemodialysis: A comparison of Cuprophan and polycarbonate. Artif Organs 1982;6:324-7.
24. Gasparotto ML, Bertoli M, Vertolli U, Ruffatti A, Stoppa ML, Di Landro D, Romagnoli GF. Biocompatibility of various dialysis membranes as assessed by coagulation assay. Contrib Nephrol 1984;37:96-100.
25. van de Wetering J, Westendorp RG, van der Hoeven JG, Stolk B, Feuth JD, Chang PC. Heparin use in continuous renal replacement procedures: The struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol 1996;7: 145-50.
26. Silvester W, Honoré P, Sieffert E, Valentine J, Wagle S, Smithies M, Bihari D. Interleukins 6 and 8, tumour necrosis factor alpha and complement D clearance by polyacrylonitrile and polysulphone membranes during haemofiltration in critically ill patients. Continuous haemofiltration in intensive care. Meeting, Paris: 1996.
27. Misset B, Timsit JF, Chevret S, Renaud B, Tamion F, Cartel J. A randomised crossover comparison of the hemodynamic response to intermittent hemodialysis and continuous hemofiltration in ICU patients with acute renal failure. Intens Care Med 1996;22:742-6.
28. Jones CH, Newstead CG, Will EJ, Davison AM. Adverse haemodynamic effects of "biocompatible" dialysis membranes in critically ill patients (abstract). Nephrol Dial Transplant 1995;10:1035.
29. Jones CH, Goutcher E, Newstead CG, Will EJ, Dean SG, Davison AM. Early hypotension during continuous high flux (CHFD) dialysis in critically ill patients (abstract). Int J Artif Org 1997;20:502.
30. Bellomo R, Farmer M, Boyce N. Combined acute respiratory and renal failure: Management by continuous hemodiafiltration. Resuscitation 1994;28:123-31.
31. Levin NW, Zasuwa G, Dumler F. Effect of membrane types on causes of death in hemodialysis patients (abstract). J Am Soc Nephrol 1991;2:335.
32. Hornberger JC, Chernew M, Petersen J, Garber AM. A multivariate analysis of mortality and hospital admissions with high-flux dialysis. J Am Soc Nephrol 1993;3:1227-37.
33. Guiterrez A, Alvestrand A, Wahren J, Bergstrom J. Effect of in vivo contact between blood and dialysis membranes on protein catabolism in humans. Kidney Int 1990;38:487-94.
34. Pascual M, Schifferli JA. Adsorption of complement factor D by polyacrylonitrile dialysis membranes. Kidney Int 1993;43: 903-11.
35. Gasche Y, Pascual M, Suter PM, Favre H, Chevrolet JC, Schifferli JA. Complement depletion during haemofiltration with polyacrilonitrile membranes. Nephrol Dial Transplant 1996;11(1):117-9.
36. Pascual M, Schifferli JA, Pannatier JG, Wauters JP. Removal of complement factor D by adsorption on polymethylmethacrylale dialysis membranes. Nephrol Dial Transplant 1993;8: 1305-11.
37. van Bommel EFH, Hesse CJ, Jutte NHPM, Zietse R, Bruining HA, Weimar W. Cytokine kinetics (TNF α, IL-1β, IL-6) during continuous hemofiltration: A laboratory and clinical study. Contrib Nephrol 1995;116:62-75.
38. Brown A, Mehta RL. Effect of CAVH membranes on transmembrane flux of TNF-α. J Am Soc Nephrol 1991;2:316.
39. Hoffmann JN, Hartl WH, Deppisch R, Faist E, Jochum M, Inthorn D. Hemofiltration in human sepsis: Evidence for elimination of immunomodulatory substances. Kidney Int 1995;48:1563-70.
40. Lonnemann G, Koch KM, Shaldon S, Dinarello CA. Studies on the ability of hemodialysis membranes to induce, bind, and clear human interleukin-1. J Lab Clin Med 1988;112:76-86.
41. Ronco C, Tetta C, Lupi A, Galloni E, Bettini MC, Sereni L, Mariano F, DeMartino A, Montrucchio G, Camussi G. Removal of platelet-activating factor in experimental continuous arteriovenous hemofiltration. Crit Care Med 1995;23(1): 99-107.
42. Lee PA, Pryor RW, Matson JR. Effects of filter pore size on efficacy of continuous hemofiltration therapy in improving morbidity and mortality in an immature swine model of Staphylococcus aureus-induced sepsis. Continuous haemofiltration in intensive care. Meeting, Paris: 1996.
43. Brivet FG, Kleinknecht DJ, Loirat P, Landais PJ. Acute renal failure in intensive care units - causes, outcome, and prognostic factors of hospital mortality: A prospective, multicenter study. Crit Care Med 1996;24:192-8.
44. Hakim RM, Wingard RL, Parker RA. Effect of the dialysis membrane in the treatment of patients with acute renal failure. New Engl J Med 1994;331:1338-12.
45. Mehta R, McDonald B, Gabbai F, Pahl M, Farkas A, Pascaul M, Fowler W, the ARF Collaborative Study Group. Continuous versus intermittent dialysis for acute renal failure (ARF) in the ICU: Results from a randomised multicenter trial (abstract). J Am Soc Nephrol 1996;7:1457.
46. Assouad M, Tseng S, Dunn K, Gonzalez J, Brennan S, Suki W. Biocompatibility of dialyzer membranes is important in the outcome of acute renal failure (abstract). J Am Soc Nephrol 1996;7:1437.
47. Gastaldello K, Melot C, Vanherweghem JL, Kahn RJ, Tielemans C. Cellulose diacetate does as well as polysulfone for the treatment of acute renal failure in the intensive care unit (abstract). J Am Soc Nephrol 1996;7:1447.
48. Simpson K, Allison MEM. Dialysis and acute renal failure: Can mortality be improved? (abstract). Nephrol Dial Transplant 1993;8:946.
49. Jones CH, Goutcher E, Newstead CG, Will EJ, Dean SG, Davison AM. Continuous dialysis for ARF in the ICU: Choice of membrane does not influence survival (abstract). J Am Soc Nephrol 1997;8:126A.